Multicancer Screening Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Multicancer Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs)), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Others), By Sample (Tissue, Blood, Saliva and Buccal Swab, Others), By Method (DNA, RNA, Proteins), By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, Other Cancer Types), By Application (Clinical, Research), By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The global multicancer screening market is anticipated to expand significantly, from USD 1.73 billion in 2025 to USD 4.06 billion by 2031, demonstrating a compound annual growth rate of 15.28%. This growth is driven by multicancer early detection (MCED) products, which are diagnostic tools employing liquid biopsy technology to identify biological signals, like circulating tumor DNA, from various types of malignancies using a single blood sample. Key factors propelling this market include the increasing global incidence of cancer and a broader shift towards preventive healthcare that emphasizes non-invasive diagnostic methods. These assays offer a distinct advantage by detecting aggressive cancers that currently lack established screening protocols, thereby offering a valuable solution for healthcare systems aiming to reduce late-stage diagnoses.The urgent demand for these tools is underscored by projections such as the American Cancer Society's estimate of approximately 2,041,910 new cancer cases in the United States in 2025. However, a significant obstacle for the market is securing reimbursement, as insurers typically postpone coverage decisions until definitive longitudinal data proves a reduction in mortality rates.
Market Driver
The global multicancer screening market is being fundamentally reshaped by advancements in liquid biopsy and next-generation sequencing, which enable the precise detection of circulating tumor DNA and methylation patterns indicative of early-stage cancers. These technological enhancements facilitate the simultaneous identification of signals from multiple cancer types from a single blood draw, thereby significantly broadening diagnostic capabilities beyond conventional single-indication screenings. The clinical effectiveness of these sophisticated platforms is increasingly validated by robust performance data, which is crucial for their widespread adoption. For example, a GRAIL study in October 2025, the 'PATHFINDER 2 Study Update', showed that incorporating the Galleri test into standard-of-care screenings led to over a seven-fold increase in cancer detection compared to standard screening alone, highlighting liquid biopsy's efficacy in addressing the critical need for tools to identify lethal cancers currently lacking standard screening protocols.Market growth is further accelerated by strategic collaborations and partnerships within the biotechnology sector, where diagnostic companies are partnering with technology and pharmaceutical leaders to secure funding and enhance commercial scalability. These alliances provide essential capital and operational support, enabling companies to navigate complex regulatory processes and expand the distribution of multicancer early detection (MCED) tests. An illustrative instance of this trend is Samsung's $110 million equity investment in GRAIL in November 2025, as reported in GRAIL's 'Third Quarter 2025 Financial Results', aimed at supporting development and commercialization. The substantial financial capacity of the wider screening sector, evidenced by Exact Sciences' $851 million revenue in the third quarter of 2025, also underscores the significant resources available for these advancements and the strong commercial foundation for future multi-cancer solutions.
Market Challenge
A significant barrier to the commercial scalability of the global multicancer screening market is the strict requirement for longitudinal mortality data to secure reimbursement. Insurers typically defer coverage decisions until the clinical utility of multicancer early detection (MCED) tests is conclusively demonstrated, which means these tests largely remain out-of-pocket expenses for most patients. This lack of payer support confines the market to a specialized segment of affluent individuals, thereby hindering the widespread adoption necessary for revenue growth and achieving economies of scale. Without a clear path to standard insurance coverage, these diagnostic tools cannot evolve from optional luxury items into fundamental elements of population health management.The adverse effects of this financial hurdle are exacerbated by existing challenges in maintaining patient adherence to screening protocols. For instance, the Prevent Cancer Foundation reported that in 2025, only 51% of U.S. adults completed their routine cancer screenings, representing a notable decrease from the prior year. This statistic underscores the already fragile nature of patient engagement, even for well-established and frequently covered procedures. Consequently, the absence of reimbursement for novel, expensive MCED assays will almost certainly lead to minimal adoption rates among the general populace, directly impeding the market's progression.
Market Trends
The market is being revolutionized by the integration of Artificial Intelligence and Deep Learning for biomarker discovery, which significantly boosts the sensitivity of assays for early-stage malignancies. These sophisticated algorithmic platforms go beyond traditional single-variant detection by analyzing intricate fragmentation patterns and methylation signatures to precisely differentiate authentic tumor-derived signals from background somatic noise. This technological advancement is crucial for detecting cancers with low shedding rates, which frequently elude standard liquid biopsy methods. For instance, Harbinger Health reported in May 2025 that its AI-enabled platform achieved 25.8% sensitivity for early-stage cancers at 98.3% specificity within a high-risk population, confirming machine learning's capacity to enhance detection accuracy.A key commercial shift involves integrating multicancer screening into corporate wellness programs, a strategy designed to circumvent existing reimbursement challenges. Diagnostic developers are increasingly bypassing conventional payer channels by directly collaborating with self-insured employers and life insurance providers, positioning MCED tests as valuable health benefits for employee retention and preventive care. This business-to-business approach generates immediate revenue streams and accumulates real-world evidence while comprehensive insurance coverage policies are still being developed. The financial effectiveness of this adoption channel is clear, as GRAIL reported in November 2025 that Galleri revenue grew 29% year-over-year to $32.8 million, primarily driven by expanded commercial partnerships and employer adoption.
Key Market Players
* Agilent Technologies, Inc.
* Atara Biotherapeutics, Inc.
* Burning Rock Biotech Limited
* Exact Sciences Corporation
* F. Hoffmann-La Roche Ltd.
* Fulgent Genetics, Inc.
* Genecast Biotechnology Co., Ltd.
* Guardant Health, Inc.
* Illumina, Inc.
* Konica Minolta, Inc.
Report Scope
In this report, the Global Multicancer Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Multicancer Screening Market, By Test Type
* Laboratory Developed Tests (LDTs)
* In-Vitro Diagnostics (IVDs)
# Multicancer Screening Market, By Technology
* Next-Generation Sequencing (NGS)
* Polymerase Chain Reaction (PCR)
* Immunohistochemistry (IHC)
* Fluorescence In-Situ Hybridization (FISH)
* Others
# Multicancer Screening Market, By Sample
* Tissue
* Blood
* Saliva and Buccal Swab
* Others
# Multicancer Screening Market, By Method
* DNA
* RNA
* Proteins
# Multicancer Screening Market, By Cancer Type
* Breast and Gynecologic
* Gastrointestinal
* Endocrine
* Genitourinary
* Skin
* Brain/Nervous System
* Sarcoma
* Hematological Malignancies
* Lung
* Head and Neck
* Other Cancer Types
# Multicancer Screening Market, By Application
* Clinical
* Research
# Multicancer Screening Market, By End User
* Hospitals
* Diagnostic and Clinical Laboratories
* Academic Research Institutions
* Others
# Multicancer Screening Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Multicancer Screening Market.
Available Customizations:
Global Multicancer Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Multicancer Screening Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs))
5.2.2. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Others)
5.2.3. By Sample (Tissue, Blood, Saliva and Buccal Swab, Others)
5.2.4. By Method (DNA, RNA, Proteins)
5.2.5. By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, Other Cancer Types)
5.2.6. By Application (Clinical, Research)
5.2.7. By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, Others)
5.2.8. By Region
5.2.9. By Company (2025)
5.3. Market Map
6. North America Multicancer Screening Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Test Type
6.2.2. By Technology
6.2.3. By Sample
6.2.4. By Method
6.2.5. By Cancer Type
6.2.6. By Application
6.2.7. By End User
6.2.8. By Country
6.3. North America: Country Analysis
6.3.1. United States Multicancer Screening Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type
6.3.1.2.2. By Technology
6.3.1.2.3. By Sample
6.3.1.2.4. By Method
6.3.1.2.5. By Cancer Type
6.3.1.2.6. By Application
6.3.1.2.7. By End User
6.3.2. Canada Multicancer Screening Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Test Type
6.3.2.2.2. By Technology
6.3.2.2.3. By Sample
6.3.2.2.4. By Method
6.3.2.2.5. By Cancer Type
6.3.2.2.6. By Application
6.3.2.2.7. By End User
6.3.3. Mexico Multicancer Screening Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test Type
6.3.3.2.2. By Technology
6.3.3.2.3. By Sample
6.3.3.2.4. By Method
6.3.3.2.5. By Cancer Type
6.3.3.2.6. By Application
6.3.3.2.7. By End User
7. Europe Multicancer Screening Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Test Type
7.2.2. By Technology
7.2.3. By Sample
7.2.4. By Method
7.2.5. By Cancer Type
7.2.6. By Application
7.2.7. By End User
7.2.8. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Multicancer Screening Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Test Type
7.3.1.2.2. By Technology
7.3.1.2.3. By Sample
7.3.1.2.4. By Method
7.3.1.2.5. By Cancer Type
7.3.1.2.6. By Application
7.3.1.2.7. By End User
7.3.2. France Multicancer Screening Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Test Type
7.3.2.2.2. By Technology
7.3.2.2.3. By Sample
7.3.2.2.4. By Method
7.3.2.2.5. By Cancer Type
7.3.2.2.6. By Application
7.3.2.2.7. By End User
7.3.3. United Kingdom Multicancer Screening Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Test Type
7.3.3.2.2. By Technology
7.3.3.2.3. By Sample
7.3.3.2.4. By Method
7.3.3.2.5. By Cancer Type
7.3.3.2.6. By Application
7.3.3.2.7. By End User
7.3.4. Italy Multicancer Screening Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Test Type
7.3.4.2.2. By Technology
7.3.4.2.3. By Sample
7.3.4.2.4. By Method
7.3.4.2.5. By Cancer Type
7.3.4.2.6. By Application
7.3.4.2.7. By End User
7.3.5. Spain Multicancer Screening Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Test Type
7.3.5.2.2. By Technology
7.3.5.2.3. By Sample
7.3.5.2.4. By Method
7.3.5.2.5. By Cancer Type
7.3.5.2.6. By Application
7.3.5.2.7. By End User
8. Asia Pacific Multicancer Screening Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Test Type
8.2.2. By Technology
8.2.3. By Sample
8.2.4. By Method
8.2.5. By Cancer Type
8.2.6. By Application
8.2.7. By End User
8.2.8. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Multicancer Screening Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type
8.3.1.2.2. By Technology
8.3.1.2.3. By Sample
8.3.1.2.4. By Method
8.3.1.2.5. By Cancer Type
8.3.1.2.6. By Application
8.3.1.2.7. By End User
8.3.2. India Multicancer Screening Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type
8.3.2.2.2. By Technology
8.3.2.2.3. By Sample
8.3.2.2.4. By Method
8.3.2.2.5. By Cancer Type
8.3.2.2.6. By Application
8.3.2.2.7. By End User
8.3.3. Japan Multicancer Screening Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type
8.3.3.2.2. By Technology
8.3.3.2.3. By Sample
8.3.3.2.4. By Method
8.3.3.2.5. By Cancer Type
8.3.3.2.6. By Application
8.3.3.2.7. By End User
8.3.4. South Korea Multicancer Screening Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Test Type
8.3.4.2.2. By Technology
8.3.4.2.3. By Sample
8.3.4.2.4. By Method
8.3.4.2.5. By Cancer Type
8.3.4.2.6. By Application
8.3.4.2.7. By End User
8.3.5. Australia Multicancer Screening Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Test Type
8.3.5.2.2. By Technology
8.3.5.2.3. By Sample
8.3.5.2.4. By Method
8.3.5.2.5. By Cancer Type
8.3.5.2.6. By Application
8.3.5.2.7. By End User
9. Middle East & Africa Multicancer Screening Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Test Type
9.2.2. By Technology
9.2.3. By Sample
9.2.4. By Method
9.2.5. By Cancer Type
9.2.6. By Application
9.2.7. By End User
9.2.8. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Multicancer Screening Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type
9.3.1.2.2. By Technology
9.3.1.2.3. By Sample
9.3.1.2.4. By Method
9.3.1.2.5. By Cancer Type
9.3.1.2.6. By Application
9.3.1.2.7. By End User
9.3.2. UAE Multicancer Screening Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type
9.3.2.2.2. By Technology
9.3.2.2.3. By Sample
9.3.2.2.4. By Method
9.3.2.2.5. By Cancer Type
9.3.2.2.6. By Application
9.3.2.2.7. By End User
9.3.3. South Africa Multicancer Screening Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type
9.3.3.2.2. By Technology
9.3.3.2.3. By Sample
9.3.3.2.4. By Method
9.3.3.2.5. By Cancer Type
9.3.3.2.6. By Application
9.3.3.2.7. By End User
10. South America Multicancer Screening Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Test Type
10.2.2. By Technology
10.2.3. By Sample
10.2.4. By Method
10.2.5. By Cancer Type
10.2.6. By Application
10.2.7. By End User
10.2.8. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Multicancer Screening Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Test Type
10.3.1.2.2. By Technology
10.3.1.2.3. By Sample
10.3.1.2.4. By Method
10.3.1.2.5. By Cancer Type
10.3.1.2.6. By Application
10.3.1.2.7. By End User
10.3.2. Colombia Multicancer Screening Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Test Type
10.3.2.2.2. By Technology
10.3.2.2.3. By Sample
10.3.2.2.4. By Method
10.3.2.2.5. By Cancer Type
10.3.2.2.6. By Application
10.3.2.2.7. By End User
10.3.3. Argentina Multicancer Screening Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Test Type
10.3.3.2.2. By Technology
10.3.3.2.3. By Sample
10.3.3.2.4. By Method
10.3.3.2.5. By Cancer Type
10.3.3.2.6. By Application
10.3.3.2.7. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Multicancer Screening Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Agilent Technologies, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Atara Biotherapeutics, Inc.
15.3. Burning Rock Biotech Limited
15.4. Exact Sciences Corporation
15.5. F. Hoffmann-La Roche Ltd.
15.6. Fulgent Genetics, Inc.
15.7. Genecast Biotechnology Co., Ltd.
15.8. Guardant Health, Inc.
15.9. Illumina, Inc.
15.10. Konica Minolta, Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們